Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High-Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management

Jack E. Ansell

doi:10.1055/s-2003-44462

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2003; 03(3): 261-270
DOI: 10.1055/s-2003-44462

Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High-Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management

Jack E. Ansell

Department of Medicine, Boston University Medical Center, Boston, MA

Abstract

ABSTRACT

Despite its widespread use, oral anticoagulation therapy suffers from a number of problems that lead to underuse and inadequate treatment. Problems include its narrow therapeutic index, the influence of many concomitant conditions or comorbidities, and the need for high-quality dose management. Poor management of oral anticoagulation is a prime factor influencing the occurrence of adverse events. As a result of these problems, special programs or anticoagulation management services (AMSs) have developed to manage oral anticoagulation. Such programs have demonstrated a significant improvement in outcomes compared with traditional or usual care (UC) by individual physicians. With the introduction of point-of-care prothrombin time monitors, the potential for patient self-testing and self-management has developed. Studies show the possibility of even further improvement in outcomes compared with UC, although the differences from those achieved with an AMS are less impressive.

KEYWORDS

Oral anticoagulation - warfarin - prothrombin time - International Normalized Ratio - adverse events - point-of-care monitoring

Full Text

References

REFERENCES

1 Ansell J. Oral anticoagulant therapy-50 years later. Arch Intern Med . 1993; 153 586-596
2 Ansell J E. Anticoagulation management as a risk factor for adverse events: grounds for improvement. J Thromb Thrombolys . 1998; 5 S13-S18
3 Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med . 1991; 151 1950-1953
4 McCrory D C, Matchar D B, Samsa G, Sanders L L, Pritchett E LC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med . 1995; 155 277-281
5 Chang H J, Bell J R, Deroo D B, Kirk J W, Wasson J H, Dartmouth Primary Care COOP Project. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med . 1990; 150 83-84
6 Ansell J, Hirsh J, Dalen J. et al . Managing oral anticoagulant therapy. Chest . 2001; 119 22S-38S
7 Loeliger E A, Poller L, Samama M, Thomson J M, van den Besselaar A H P M, Vermylen J, Verstraete M. Questions and answers on prothrombin time standardization in oral anticoagulant control. Thromb Haemostas . 1985; 54 515-517
8 Ansell J E, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring and patient self-management. Am Heart J . 1996; 132 1095-1100
9 Ansell J E. Patient self-testing and patient self-management of oral anticoagulation with point-of-care testing. In: GJ Kost, ed. Principles and Practice of Point-of-Care Testing Philadelphia: Lippincott Williams & Wilkins; 2002: 368-375
10 Gitter M J, Jaeger T M, Petterson T M, Gersh B J, Silverstein M D. Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, Minnesota. Mayo Clinic Proc . 1995; 70 725-733
11 Beyth R J, Quinn L M, Landefeld C S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med . 1998; 105 91-99
12 Fihn S D, McDonell M, Martin D. et al . Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med . 1993; 118 511-520
13 van der Meer J F, Rosendaal F R, Vandenbrouke J P, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med . 1993; 153 1557-1562
14 Cannegieter S C, Rosendaal F R, Wintzen A R, van der Meer J M F, Vandenbroucke J P, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med . 1995; 33 11-17
15 Hylek E M, Singer D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med . 1994; 120 897-902
16 Hylek E M, Skates S J, Sheehan M A, Singer D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med . 1996; 335 540-546
17 Petitti D B, Strom B L, Melmon K L. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol . 1989; 42 759-764
18 Landefeld C S, Rosenblatt M W, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remedial lesions. Am J Med . 1989; 87 153-159
19 White R H, McKittrick T, Takakuwa J. et al . Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med . 1996; 156 1197-1201
20 Launbjerg J, Egeblad H, Heaf J, Nielsen N H, Fugleholm A M, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med . 1991; 229 351-355
21 Cortelazzo S, Finazzi G, Viero P. et al . Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Hemost . 1993; 69 316-320
22 Palareti G, Leali N, Coccheri S. et al . Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet . 1996; 348 423-428
23 Landefeld S, Beyth R J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med . 1993; 95 315-328
24 Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group. Lancet . 1982; I 62-68
25 Charney R, Leddomado E, Rose D N, Fuster V. Anticoagulation clinics and the monitoring of anticoagulant therapy. Int J Cardiol . 1988; 18 197-206
26 Forfar J C. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J . 1982; 103 445-446
27 Errichetti A M, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. Arch Intern Med . 1984; 144 1966-1968
28 Petty G W, Lennihan L, Mohr J P. et al . Complications of long-term anticoagulation. Ann Neurol . 1988; 23 570-574
29 Bussey H I, Rospond R M, Quandt C M, Clark G M. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy . 1989; 9 214-219
30 Gurwitz J, Goldberg R, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med . 1988; 148 1733-1736
31 McInnes G T, Helenglass G. The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond . 1987; 21 42-45
32 Wickramasinghe L SP, Basu S K, Bansal S K. Long-term oral anticoagulant therapy in elderly patients. Age Aging . 1988; 17 388-396
33 Joglekar M, Mohanaruban K, Bayer A J, Pathy M SJ. Can old people on oral anticoagulants be safely managed as outpatients?. Postgrad Med J . 1988; 64 775-777
34 Issacs C, Paltiel O, Blake G, Beaudet M, Conochie L, Leclerc J. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture. Am J Med . 1994; 96 487-491
35 Davis F B, Estruch M T, Samson-Cervera E B. et al . Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. Arch Intern Med . 1977; 137 197-202
36 Landefeld C S, Goldman L. Major bleeding in outpatients treated with warfarin. Incidence and prediction by factors known at the start of outpatient therapy. Am J Med . 1989; 87 144-152
37 Coon W W, Willis P W. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med . 1974; 133 386-392
38 Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med . 1996; 156 409-416
39 Fihn S D, Callahan C M, Martin D C. et al . The risk for and severity of bleeding complication in elderly patients treated with warfarin. Ann Intern Med . 1996; 124 970-979
40 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet . 1996; 348 633-638
41 McCormick D, Gurwitz J H, Goldberg J, Ansell J. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. J Thromb Thrombolys . 1999; 7 157-163
42 Pettiti D B, Strom B L, Melmon K L. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med . 1986; 81 255-259
43 Ansell J E, Buttaro M L, Voltis T O, Knowlton C H, Anticoagulation Guidelines Task Force. Consensus guidelines for coordinated outpatient oral anticoagulation therapy. Annals of Pharmacotherapy . 1997; 31 604-615
44 Conte R R, Kehoe W A, Nielson N, Lodhia H. Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm . 1986; 43 2460-2464
45 Seabrook G R, Karp D, Schmitt D D, Bandyk D F. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surg . 1990; 160 501-504
46 Palareti G, Manotti C, D'Angelo A. et al . Thrombotic events during anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost . 1997; 78 1438-1443
47 Garabedian-Ruffalo S M, Gray D R, Sax M J. et al . Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm . 1985; 42 304-308
48 Wilt V M, Gums J G, Amhed O I, Moore L M. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy . 1995; 15 732-739
49 Chiquette E, Amato M G, Bussey H I. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med . 1998; 158 1641-1647
50 Matchar D B, Samsa G P, Cohen S J, Oddone E Z, Jurgelski A E. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the Managing Anticoagulation Services Trial. Am J Med . 2002; 113 42-51
51 Gray D R, Garabedian-Ruffalo S M, Chretien S D. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm . 1985; 19 575-580
52 Lucas F V, Duncan A, Jay R. et al . A novel whole blood capillary technique for measuring prothrombin time. Am J Clin Pathol . 1987; 88 442-446
53 Yano Y, Kambayashi J, Murata K. et al . Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor. Thromb Res . 1992; 66 583-590
54 Weibert R T, Adler D S. Evaluation of a capillary whole blood prothrombin time measurement system. Clin Pharm . 1989; 8 864-867
55 Oberhardt B J, Dermott S C, Taylor M, Alkadi Z Y, Abruzzini A F, Gresalfi N J. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. Clin Chem . 1991; 37 520-526
56 Rose V L, Dermott S C, Murray B F. et al . Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer. Arch Pathol Lab Med . 1993; 117 611-617
57 Fabbrini N, Messmore H, Balbale S. et al . Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting. Blood . 1995; 86 (suppl 1) 869a
58 Ansell J, Becker D, Andrew M. et al . Accurate and precise prothrombin time measurement in a multicenter anticoagulation trial employing patient self-testing. Blood . 1995; 86 (suppl 1) 864a
59 Ansell J E, Zweig S, Meyer B, Zehnder J, Lewis J. Performance of the Avocet_PT prothrombin time system. Blood . 1998; 92 (suppl 1) 112b
60 Jennings I, Luddington R J, Baglin T. Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. J Clin Pathol . 1991; 44 950-953
61 McCurdy S A, White R H. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. Arch Intern Med . 1992; 152 589-592
62 Tripodi A, Arbini A A, Chantarangkul V. et al . Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the International Normalized Ratio?. Thromb Haemostas . 1993; 70 921-924
63 van den Besselaar A H P M, Breddin K, Lutze G. et al . Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coag Fibrinolys . 1995; 6 726-732
64 Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci P M. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy. Thromb Haemost . 1997; 78 855-858
65 Kaatz A A, White R H, Hill J. et al . Accuracy of laboratory and portable monitor International Normalized Ratio determinations. Arch Intern Med . 1995; 155 1861-1867
66 Portable prothrombin time monitors. Med Lett Drugs Ther 1995 Mar 17;37(944):24 .
67 Byeth R J, Quinn L, Landefeld C S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized controlled trial. Ann Intern Med . 2000; 133 687-695
68 Horstkotte D, Piper C, Wiemer M, Schulte H D, Schultheiss H-P. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy. Eur Heart J . 1996; 17(suppl) 230
69 Hasenkam J M, Kimose I I, Knudsen L. et al . Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg . 1997; 11 935-942
70 Sawicki P T. et al . A structured teaching and self-management program for patients receiving oral anticoagulation. A randomized controlled trial. JAMA . 1999; 281 145-150
71 Kortke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?. Ann Thorac Surg . 2001; 72 44-48
72 White R H, McCurdy S A, von Marensdorff H, Woodruff D E, Leftgoff L. Home prothrombin time monitoring after initiation of warfarin therapy. Ann Intern Med . 1989; 111 730-737
73 Kaatz S, Elston-Lafata J, Gooldy S. Anticoagulation therapy home and office monitoring evaluation study. J Thromb Thrombolys . 2001; 12 111
74 Ansell J, Patel N, Ostrovsky D, Nozzolillo E, Peterson A M, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med . 1995; 155 2185-2189
75 Watzke H H, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost . 2000; 83 661-665
76 Cromheecke M E, Levi M, Colly L P. et al . Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet . 2000; 356 97-102
77 Gadisseur A PA, Breukink-Engbers W GM, van der Meer J M F, Rosendaal F R. Comparison of the quality of oral anticoagulant therapy through patient self-management versus management by specialised anticoagulation clinics in the Netherlands. Thromb Haemost 2001;86(suppl):abst #OC161.